Difference between revisions of "Cyclophosphamide (Cytoxan)"

Revision as of 19:23, 9 June 2023

General information

Class/mechanism: Alkylating agent; transformed primarily in the liver to active metabolites which alkylate and crosslink DNA.^[1]^[2]
Route: IV, PO
Extravasation: irritant or neutral, depending on reference; n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is established (work in progress)

Non-Hodgkin lymphoma

Diseases for which it is used

Diseases for which it was used

Patient drug information

History of changes in FDA indication

1959-11-16: initial FDA approval
2012-03-31 (oldest label available at Drugs @ FDA): Approved for malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt lymphoma; multiple myeloma, leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration); mycosis fungoides (advanced disease); neuroblastoma (disseminated disease); adenocarcinoma of ovary; retinoblastoma; carcinoma of the breast (No supporting studies are cited)

History of changes in PMDA indication

2015-06-26: revised indication and a new dosage for the relief of symptoms of malignant lymphoma.
2019-03-26: New indication for the treatment prior to tumor-specific T-cell infusion therapy.
2021-08-21: new indication and a new dosage for the treatment of systemic AL amyloidosis.

Also known as

Code names: Asta B 518, B-518, WR-138719
Generic names: CP monohydrate, CPM, cyclophosphamid monohydrate, cyclophosphamide monohydrate
Brand names:

Synonyms
Alkyloxan	Biodoxan	Carloxan	Ciclofosfamida	Ciclokebir	Cicloxal	Clafen	Claphene
Cyclam	Cycloblastin	Cycloblastine	CYCLO-cell	Cycloferon	Cyclomide	Cyclophar	Cyclophospham
Cyclophosphamid	Cyclophosphane	Cyclostin	Cyclostine	Cyclotox	Cycloxan	Cycram	Cydoxan
Cyklofosfamid	Cyphos	Cytophosphan	Cytoxan	Cytoxan Lyophilized	Endoxan	Endoxan-N	Endoxana
Enduxan	Formitex	Fosfaseron	Genoxal	Genuxal	Hidrofosmin	Ledoxan	Ledoxina
Mitoxan	Neophos	Neosar	Oncomide	Oncophos	Procytox	Revimmune	Sendoxan
Siklofos	Syklofosfamid	Tymtran	Zuviphos	Zycram	Zytoxan

References

[insert-1] 1.0 ^1.1 ^1.2 Cyclophosphamide (Cytoxan) package insert

[2] Cyclophosphamide (Cytoxan) package insert (locally hosted backup)

[3] Cyclophosphamide (Cytoxan) patient drug information (Chemocare)

[4] Cyclophosphamide (Cytoxan) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

@@ Line 70: / Line 70: @@
 *2012-03-31 (oldest label available at Drugs @ FDA): Approved for [[:Category:Lymphomas|malignant lymphomas]] (Stages III and IV of the Ann Arbor staging system), [[Hodgkin lymphoma|Hodgkin’s disease]], lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, [[Diffuse large B-cell lymphoma|histiocytic lymphoma]], [[Burkitt lymphoma]]; [[multiple myeloma]], leukemias: [[Chronic lymphocytic leukemia]], [[Chronic myeloid leukemia|chronic granulocytic leukemia]] (it is usually ineffective in acute blastic crisis), [[Acute myeloid leukemia|acute myelogenous and monocytic leukemia]], [[:Category:Acute lymphoblastic leukemias|acute lymphoblastic (stem-cell) leukemia]] in children (cyclophosphamide given during remission is effective in prolonging its duration); [[Cutaneous T-cell lymphoma|mycosis fungoides]] (advanced disease); [[neuroblastoma]] (disseminated disease); [[Ovarian cancer|adenocarcinoma of ovary]]; [[retinoblastoma]]; [[Breast cancer|carcinoma of the breast]] ''(No supporting studies are cited)''
 ==History of changes in PMDA indication==
+*2015-06-26: revised indication and a new dosage for the relief of symptoms of [[:Category:Lymphomas|malignant lymphoma]].
 *2019-03-26: New indication for the treatment prior to tumor-specific T-cell infusion therapy.
 *2021-08-21: new indication and a new dosage for the treatment of [[Light-chain (AL) amyloidosis|systemic AL amyloidosis]].